1. Home
  2. MRVI vs HCAT Comparison

MRVI vs HCAT Comparison

Compare MRVI & HCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRVI
  • HCAT
  • Stock Information
  • Founded
  • MRVI 2014
  • HCAT 2008
  • Country
  • MRVI United States
  • HCAT United States
  • Employees
  • MRVI N/A
  • HCAT N/A
  • Industry
  • MRVI Biotechnology: Pharmaceutical Preparations
  • HCAT Computer Software: Programming Data Processing
  • Sector
  • MRVI Health Care
  • HCAT Technology
  • Exchange
  • MRVI Nasdaq
  • HCAT Nasdaq
  • Market Cap
  • MRVI 262.9M
  • HCAT 259.8M
  • IPO Year
  • MRVI 2020
  • HCAT 2019
  • Fundamental
  • Price
  • MRVI $2.12
  • HCAT $4.52
  • Analyst Decision
  • MRVI Hold
  • HCAT Buy
  • Analyst Count
  • MRVI 9
  • HCAT 11
  • Target Price
  • MRVI $6.54
  • HCAT $8.00
  • AVG Volume (30 Days)
  • MRVI 1.7M
  • HCAT 528.4K
  • Earning Date
  • MRVI 05-12-2025
  • HCAT 05-07-2025
  • Dividend Yield
  • MRVI N/A
  • HCAT N/A
  • EPS Growth
  • MRVI N/A
  • HCAT N/A
  • EPS
  • MRVI N/A
  • HCAT N/A
  • Revenue
  • MRVI $259,185,000.00
  • HCAT $311,274,000.00
  • Revenue This Year
  • MRVI N/A
  • HCAT $11.18
  • Revenue Next Year
  • MRVI $11.14
  • HCAT $9.74
  • P/E Ratio
  • MRVI N/A
  • HCAT N/A
  • Revenue Growth
  • MRVI N/A
  • HCAT 4.88
  • 52 Week Low
  • MRVI $1.67
  • HCAT $3.56
  • 52 Week High
  • MRVI $11.56
  • HCAT $9.24
  • Technical
  • Relative Strength Index (RSI)
  • MRVI 50.73
  • HCAT 61.75
  • Support Level
  • MRVI $1.96
  • HCAT $4.08
  • Resistance Level
  • MRVI $2.16
  • HCAT $5.06
  • Average True Range (ATR)
  • MRVI 0.12
  • HCAT 0.27
  • MACD
  • MRVI 0.04
  • HCAT 0.07
  • Stochastic Oscillator
  • MRVI 65.31
  • HCAT 57.05

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

About HCAT Health Catalyst Inc

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

Share on Social Networks: